Multi-alleles predict primary non-response to infliximab therapy in Crohn's disease
{{output}}
Background: Infliximab (IFX) is the first-line treatment for patients with Crohn's disease (CD) and is noted for its relatively high cost. The therapeutic efficacy of IFX has noticeable individual differences. Known single-gene p... ...